Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart fat scans could unlock new heart failure treatments

NCT ID NCT07178145

Knowledge-focused Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study uses advanced MRI to measure the fat around the heart in people with a type of heart failure called HFpEF. Researchers want to see if the fat's composition, not just its amount, is linked to disease severity. They will also test if a diabetes drug called semaglutide changes this fat in a way that improves heart function. About 192 adults aged 18-90 with HFpEF risk factors will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 192 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years - 90 years; * LVEF ≥ 50%; * ≥ 2 risk factors for HFpEF or symptoms that could be related to HFpEF (e.g., dyspnea, orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, pulmonary edema, etc); * Not currently being treated with GLP-1RA therapy. Exclusion Criteria: * • Previously or currently reduced EF (\<50%), including heart transplant; (2) Obstructive un-revascularized coronary disease by coronary CT or invasive coronary angiography; * MI/PCI/CABG within the past 6 months; * Untreated severe stenotic or regurgitant valvular disease; * Infiltrative cardiomyopathy (Fabry/HCM/sarcoid/amyloid, etc); * Myocarditis; * Claustrophobia/inability to tolerate MRI; * Implants that are a contraindication for MRI or may negatively impact image quality (e.g. pacemakers and ICDs); * Active systemic inflammatory disorder; * Atrial fibrillation with rapid ventricular response at time of study; and * Hemodynamic instability * Pregnancy * Prisoners * Inability to provide informed consent Exclusion Criteria for Optional Cardiac Stress Imaging Procedure * allergy to gadolinium-based contrast agents * Acute kidney injury * Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m² * Hepatorenal syndrome * History of liver transplant * High-grade atrioventricular (AV) block * Active asthma exacerbation * Known allergy to vasodilator agents * Recent seizure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epicardial adipose tissue are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epicardial adipose tissue Heart failure preserved ejection fraction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Virginia

    RECRUITING

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.